BiotechTube

SHR0302 + SHR0302 placebo

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis

Trial Timeline

Oct 14, 2020 → May 12, 2023

NCT ID
NCT04481139

About SHR0302 + SHR0302 placebo

SHR0302 + SHR0302 placebo is a phase 2/3 stage product being developed by Jiangsu Hengrui Medicine for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04481139. Target conditions include Ankylosing Spondylitis.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (2)

NCT IDPhaseStatus
NCT05324631Phase 3UNKNOWN
NCT04481139Phase 2/3Completed

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
33
InfliximabCelltrionPhase 1
33
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
adalimumabEisaiPhase 3
77
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
77
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
85
Golimumab + PlaceboJohnson & JohnsonPhase 3
77
GolimumabJohnson & JohnsonApproved
85
placebo for risankizumab + risankizumabAbbViePhase 2
52
AdalimumabAbbVieApproved
85
Upadacitinib + PlaceboAbbViePhase 2
52
AdalimumabAbbViePre-clinical
23
infliximab + PlaceboMerckPhase 3
77
InfliximabMerckApproved
85
Infliximab + Placebo + NaproxenMerckPhase 3
77
InfliximabMerckPre-clinical
23
GolimumabMerckApproved
85
RemicadeMerckApproved
85
RemicadeMerckApproved
85
InfliximabMerckApproved
85

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85